The pentose phosphate pathway (PPP) plays a role in the phosphorylation of glucose and it is responsible for producing ribose-5-phosphate and reduced nicotinamide adenine dinucleotide phosphate (NADPH). This pathway is vital for the production of NADPH, which is responsible for the synthesis of lipids and the maintenance of redox balance in a cell. There are many systems dependent on NADPH, including enzymes involved in lipid production such as 3-hydroxy-3-methylglutaryl-CoA reductase and the NADPH-cytochromeP450 oxidoreductase that is required for drug metabolism, steroid biosynthesis, and many other functions. The rate-limiting enzyme of the pentose phosphate pathway is glucose-6-phosphate dehydrogenase (G6PD) and the enzyme is responsible for producing the NADPH as a byproduct of PPP. But overexpression or hyperactivity of the G6PD enzyme causes excessive NADPH synthesis in cells. The development of several diseases such as cancer, obesity, diabetes, and infectious diseases is highly dependent on NADPH bioavailability. Although NADPH is produced by 6-phosphogluconate dehydrogenase, malic enzyme, and isocitrate dehydrogenase enzymes, except G6PD enzyme, G6PD appears to be of unique importance to many cellular processes that use NADPH, as inhibition of G6PD impairs many cellular processes that are dependent on NADPH.
G6PD is at the nexus of many essential metabolic pathways. Because of these factors, G6PD is an outstanding target for any intracellular processes control and treatment of many diseases. This Research Topic is aimed at the screening of new drugs for the target, the design and synthesis of novel drugs, and the determination of their possible mechanisms.
In this Research Topic, we welcome original research articles, reviews, opinion, perspective, and systematic review, but are not limited to:
- Recent advancements in natural and synthetic compounds in the therapy of the disease.
- The identification of new active compounds and their possible mechanisms in treating of the disease.
The pentose phosphate pathway (PPP) plays a role in the phosphorylation of glucose and it is responsible for producing ribose-5-phosphate and reduced nicotinamide adenine dinucleotide phosphate (NADPH). This pathway is vital for the production of NADPH, which is responsible for the synthesis of lipids and the maintenance of redox balance in a cell. There are many systems dependent on NADPH, including enzymes involved in lipid production such as 3-hydroxy-3-methylglutaryl-CoA reductase and the NADPH-cytochromeP450 oxidoreductase that is required for drug metabolism, steroid biosynthesis, and many other functions. The rate-limiting enzyme of the pentose phosphate pathway is glucose-6-phosphate dehydrogenase (G6PD) and the enzyme is responsible for producing the NADPH as a byproduct of PPP. But overexpression or hyperactivity of the G6PD enzyme causes excessive NADPH synthesis in cells. The development of several diseases such as cancer, obesity, diabetes, and infectious diseases is highly dependent on NADPH bioavailability. Although NADPH is produced by 6-phosphogluconate dehydrogenase, malic enzyme, and isocitrate dehydrogenase enzymes, except G6PD enzyme, G6PD appears to be of unique importance to many cellular processes that use NADPH, as inhibition of G6PD impairs many cellular processes that are dependent on NADPH.
G6PD is at the nexus of many essential metabolic pathways. Because of these factors, G6PD is an outstanding target for any intracellular processes control and treatment of many diseases. This Research Topic is aimed at the screening of new drugs for the target, the design and synthesis of novel drugs, and the determination of their possible mechanisms.
In this Research Topic, we welcome original research articles, reviews, opinion, perspective, and systematic review, but are not limited to:
- Recent advancements in natural and synthetic compounds in the therapy of the disease.
- The identification of new active compounds and their possible mechanisms in treating of the disease.
